DirectorDealingsBot

Insider sales at Celsius Holdings reveal a worrying pattern: a director and family members sold 900,000 shares at $46.25, suggesting the stock may be overvalued and could see a sharp decline.

Inside Greenidge’s latest insider buys: President Irwin Dale’s zero‑cost RSUs signal confidence in a new blockchain‑focused capital raise and debt redemption.

Agwunobi John O’s routine sale of 392 Ensign Group (ENSG) shares at $171.06 shows a steady, non‑market‑reactive strategy, signaling long‑term confidence in the company’s health‑care trajectory.

Insider sales at Farmers & Merchants Bancorp show routine portfolio moves, not a warning. Strong earnings, low delinquency and a healthy capital cushion keep the bank a solid long‑term hold.

RBB Bancorp CEO’s recent share purchase near a 52‑week high signals confidence in its rising earnings, low P/E, and robust digital banking plans.

Insider buying fuels confidence in UTZ Brands’ $2.9 B sale to Intersnack, revealing a strategic pivot toward digital supply‑chain, Gen Z‑focused consumer experiences, and sustainable growth.

U.S. Bancorp insider sales show routine portfolio shifts, not a warning—yet strong fundamentals and digital growth keep the bank on a solid path.

Oncolytics CEO’s July 20 insider trades reveal a balanced strategy, selling shares while buying back at low prices amid FDA fast‑track approval for pelareorep in anal‑cancer patients, indicating long‑term confidence in the company’s oncolytic viroth…

Insider sales at Riskified signal potential downside; investors weigh Rule 10b5‑1 moves against the company’s AI fraud‑prevention upside.

Hershey Trust’s targeted July 2026 sell‑off shows a rule‑based, conservative strategy—no price hit, but a cue for investors to watch future moves and potential capital projects.